Efficacy of antiemetic therapy in patients undergoing laparoscopic cholecystectomy  by Llanes-Garza, H.A. et al.
Medicina Universitaria. 2015;17(68):143--146
www.elsevier.es/rmuanl
ORIGINAL ARTICLE
Efﬁcacy  of  antiemetic  therapy  in patients  undergoing
laparoscopic cholecystectomy
H.A. Llanes-Garzaa,∗, N.G. López-Cabreraa, R. Cacho-De la Vegaa, D. Palacios-Riosa,
A.L.  Millan-Corralesa, M. Pacheco-Juáreza, E. Cárdenas-Estradab
a Anesthesiology  Department  at  the  ‘‘José  Eleuterio  González’’  University  Hospital  at  the  School  of  Medicine  of  the  Autonomous
University of  Nuevo  Leon,  Mexico
b Center  of  Research  and  Development  in  Health  Sciences  at  the  UANL  (CIDICS),  Mexico
Received 23  April  2015;  accepted  27  April  2015
Available  online  19  August  2015
KEYWORDS
Laparoscopy;
Cholecistecomy;
Antiemetics;
Ondansetron;
Metoclopramide
Abstract
Introduction:  A  high  incidence  of  postoperative  nausea  and  vomiting  has  been  observed  in
patients undergoing  laparoscopic  cholecystectomy  (20--40%).  This  causes  an  increase  in  patient
discomfort,  a  delay  in  recovery,  and  an  increase  in  hospital  stay.
Objective:  Compare  the  efﬁcacy  of  ondansetron  plus  metoclopramide  and  ondansetron  alone
in the  control  of  postoperative  nausea  and  vomiting  in  patients  undergoing  laparoscopic  chole-
cystectomy.
Material  and  methods:  A  comparative,  prospective,  experimental,  longitudinal  double  blind
study was  performed  with  30  patients  programmed  for  laparoscopic  cholecystectomy.  The  Apfel
score was  applied  postoperatively.  Patients  were  divided  into  two  groups  with  15  participants.
Metoclopramide  10  mg  and  ondansetron  4  mg  were  administered  in  the  ﬁrst  Group  (A),  and
ondansetron  4  mg  in  the  second  Group  (B),  after  induction  of  anesthesia.  Nausea  and  vomiting
were evaluated  for  24  h  postoperatively  using  a  Likert  scale.
Results: Of  the  patients  who  presented  nausea,  the  condition  was  mild.  The  patient  who  pre-
sented vomiting,  vomited  only  once.  Neither  group  required  rescue  drugs.  Regarding  the  Apfel
score, there  was  no  correlation  between  the  percentage  of  stratiﬁed  risk  and  the  patients  who
presented  postoperative  nausea  and  vomiting.
Conclusions:  No  statistically  signiﬁcant  difference  was  observed  between  ondansetron  plus
metoclopramide  and  ondansetron  alone  in  patients  subjected  to  laparoscopic  cholecystectomy.
© 2015  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Universidad  Autónoma  de  Nuevo
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ntroduction
aparoscopic  cholecystectomy  is  the  golden  choice  in  the
reatment  of  gallbladder  disease  and  has  been  proven  to
e  better  in  the  cost-effectiveness-efﬁciency  relation  when
ompared  to  open  surgery.1,2
Out  of  100  laparoscopic  cholecystectomies  performed,
etween  20  and  42%  present  a  complication,  postoperative
ausea  and  vomiting  (PONV),  which  delays  the  patients’  dis-
harge.  It  translates  into  greater  postoperative  discomfort
nd  distress  for  patients,  on  top  of  the  fact  that  they  usu-
lly  remain  50%  longer  in  the  recovery  room,  thus  altering
he  patient  ﬂow  of  the  hospital  and  increasing  internment
osts.  PONV  can  also  increase  suture  tension  and  the  risk
f  pulmonary  aspiration,  which  could  lead  to  pneumonia  or
neumonitis  and  the  increase  of  intracranial  pressure.  Its
tiology  includes  dehydration  by  fasting,  the  use  of  opioids,
itrous  oxide,  inhaled  anesthetics  in  general  anesthesia,
neumoperitoneum,  CO2 and  handling  of  the  parietal  peri-
oneum  with  vagal  stimulation.  The  risk  of  PONV  ought  to
e  stratiﬁed  preoperatively  and  reduced,  adapting  anes-
hetic  techniques  or  using  the  available  pharmacological
esources.3--5
There  are  different  PONV  predictive  models  that,  if
pplied,  can  help  prevent  its  presence.  When  ranked  by  sen-
itivity,  the  Apfel  score  is  the  most  used  in  the  reviewed
ibliography  (see  Table  1).6
The  different  vomit  stimuli  are  related  to  the  dopamin-
rgic,  histaminergic,  serotoninergic,  muscarinic  and  opioid
eceptors  located  in  the  central  pathways  (reticular
ormation  of  the  medulla)  and  peripheral  pathways  (gas-
rointestinal  system),  thus  their  blockage  is  a  mechanism
f  antiemetic  medications.
There  are  different  antiemetic  families;  H1  antihis-
amines,  anticholinergic,  steroids,  phenothiazine,  buty-
ophenones,  dopamine  antagonists  and  5-HT3 receptor
ntagonists.  These  medications  are  currently  being  uti-
ized  in  an  isolated  or  combined  form.  Metoclopramide,
n  antiemetic  from  the  benzamide  group  with  anti-
opaminergic  and  central  and  peripheral  antiemetics,  acts
n  the  upper  gastrointestinal  tracts  for  2  h  (10--20  mg  for
very  70  kg  on  average  in  adults).  Ondansetron  is  an  antag-
nist  of  the  serotonin  receptor  (5-HT3).  It  has  been  used
or  some  years  to  control  nausea  and  vomiting  induced  by
Table  1  Apfel  risk  assessment  scale  for  nausea  and
vomiting.
Risk  factors  Points  Risk
Female  1  Low  risk  (0--1
points)  10--20%
Non-smoker  1  Moderate  risk  (2
points)  40%
Previous  history  of
postoperative  vomiting
and/or  motion  sickness
1  High  risk  (3--4
points)  60--80%
Use of  postoperative  opioids  1
I. Bel Marcoval. Estratiﬁcación del riesgo, proﬁlaxis y
tratamiento de las náuseas y vómitos postoperatorios. Rev. Esp.
Anestesiol. Reanim. 2006; 53: 301--311.
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hemotherapy  and  radiotherapy.  It  has  central  and  periph-
ral  effects.  Doses  of  4  mg  peak  plasmatic  concentrations
re  reached  in  approximately  7--11  min  depending  of  the
peed  of  administration.7--9
The  objective  of  our  study  was  to  compare  the  clinical
ffectiveness  of  ondansetron  with  metoclopramide  in  a  sin-
le  dose  and  ondansetron  in  an  isolated  form  in  the  control
f  postoperative  nausea  and  vomiting  in  patients  undergoing
aparoscopic  cholecystectomy.
ethods and materials
he  current  study  included  patients  who  were  programmed
or  elective  laparoscopic  cholecystectomies  at  the  surgical
ard  from  the  ‘‘Dr.  José  E.  Gonzalez’’  University  hospi-
al  of  the  Autonomous  University  of  Nuevo  León,  México.
he  study  consisted  of  a  comparative,  prospective,  exper-
mental,  longitudinal  double  blind  study.  Our  institution’s
thics  Committee  reviewed  and  authorized  the  project.  The
nclusion  criteria  were  patients  undergoing  elective  laparo-
copic  cholecystectomy,  between  18  and  60  years  old,  who
eighted  between  50  and  90  kg.  ASA  I-II  patients  and  both
enders  were  included.  The  exclusion  criteria  were  ASA  III-
V  patients,  under  18  years  old,  allergic  to  the  medications
ncluded  in  this  study,  pregnant  women,  patients  who  were
hronically  taking  prokinetics,  patients  with  an  Apfel  score
f  3--4  and  patients  who  required  any  other  medication  dur-
ng  induction.  Within  exclusion  criteria  were  patients  who
resented  allergic  reactions  during  the  procedure,  those
ith  conversions  to  open  surgery  and  those  who  required
he  use  of  other  rescue  antiemetic  medications.
The  sample  calculation  was  performed  based  on  the  arti-
le  ‘‘Risk  stratiﬁcation,  nausea  and  vomiting  prophylaxis’’
ostoperative,  published  by  Dr.  I  Bel  Marcoval  et  al.,  in  the
panish  magazine  of  Anesthesiology  in  2006,  using  the  fol-
owing  formula,  ((2*2)/(−  +  d)2)*(Z1  −  ˛2 +  Z1  −  ˇ)2.  We
btained  a  sample  size  of  30  patients,  via  a  non-inferiority
rial  and  with  a  conﬁdence  level  of  5%  (p  <  0.05).  The  sample
as  divided  into  two  groups  of  15  patients  each.  Metoclo-
ramide  10  mg  and  ondansetron  4  mg  were  administered  in
he  ﬁrst  Group  (A),  and  ondansetron  4 mg  in  the  second
roup  (B),  after  induction  of  anesthesia.
The  general  objective  of  our  study  was  to  compare  the
linical  effectiveness  of  ondansetron  with  metoclopramide
n  a single  dose  and  ondansetron  in  an  isolated  form  in  the
ontrol  of  postoperative  nausea  and  vomiting  in  patients
ndergoing  laparoscopic  cholecystectomy.  Within  our  sec-
ndary  objectives  were  the  application  and  comparison  of
he  Apfel  scale  for  the  risk  of  nausea  and  vomiting  in  the
reoperative  of  both  groups,  to  assess  the  antiemetic  efﬁ-
acy  of  both  medications  for  their  study  groups,  and  the
equirement  of  rescue  medications.
In the  pre-surgical  area,  demographic  data  was  col-
ected,  such  as  age,  gender  and  body  mass  index  (BMI).
heir  ASA  was  determined  based  on  their  pathological
nd  non-pathological  background.  In  addition,  we  obtained
he  signature  of  the  patient  (or  tutor)  for  the  informed
onsents.  The  patients  were  pre-medicated  with  raniti-
ine  and  midazolam,  and  were  evaluated  with  the  Apfel
core.  After  the  patient  entered  the  operation  room
OR),  monitoring  and  the  taking  of  basal  vital  signs  were
145
Table  2  Data  obtained  in  relation  to  the  Apfel  scale.
Variable  measure  Number  of
positive  patients
Positive
variables
1  point  (20%) 5
2 points  (40%)  12
3 points  (60%)  12
4 points  (80%)  1
V.  Female  27
V.  Non-smoker  20
V.  Previous  history  of
postoperative  vomiting
and/or  motion  sickness
11
V.  Use  of  postoperative
opioids
11
Patient  with  vomiting  1  2
Patient  with  nausea  no.  1  1  1
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conducted.  Anesthetic  induction  consisted  of  fentanyl
3  mcg/kg,  etomidate  0.2  mg/kg  and  atracurium  0.4  mg/kg
with  isoﬂurane-based  anesthetic  maintenance.  The  ﬁrst
group  (A)  received  ondansetron  4  mg  and  metoclopramide
10  mg  in  a  single  dose  in  a  slow  infusion  for  20  min  after
anesthetic  induction  and  the  second  group  (B)  received
ondansetron  4  mg  in  the  same  fashion.  The  degree  of  nau-
sea  and  vomiting  was  evaluated  with  the  Likert  scale  of  5
points  (0  =  none,  1  =  preview,  2  =  mild,  3  =  moderate,  4  =  high,
5  =  intense  retching  and  presence  of  vomit).  Patients  were
evaluated  immediately  and  24  h  after  the  postoperative
period.  Basal  time  measurements  were  conducted  4,  8,  12
and  24  h  later.
Statistical  analysis  was  performed  via  a  non-inferiority
trial;  qualitative  and  quantitative  variables  were  used.  An
alpha  value  of  0.05  was  also  used  and  null  hypothesis  was
rejected  when  the  critical  value  was  under  0.05.  Nonpara-
metric  tests  were  used  (x2 and  parametric  (t  student)).  The
electronic  data  processing  and  statistical  methods  (descrip-
tive  and  inferential)  were  performed  using  STATA-IC-10-2010
software.
Results
In  the  period,  a  total  number  of  30  patients  were  obtained
and  divided  into  2  groups;  group  A  (metoclopramide  and
ondansetron)  with  15  patients  and  group  B  (ondansetron)
with  15  patients.
Group  A  consisted  of  2  male  patients  (13.3%),  and  13
female  (86.6%)  patients,  while  group  B  consisted  of  1  male
(6.66%)  and  14  females  (93.3%).  The  difference  between  the
two  groups  was  not  statistically  signiﬁcant.  Regarding  age
range,  11  patients  were  between  the  ages  of  18  and  29,  8
of  them  were  between  30  and  39,  5  were  between  40  and
49  and  6  were  between  50  and  59.  Group  A  consisted  of  4
patients  between  the  ages  of  18  and  29,  5  between  30  and
39,  3  between  40  and  49  and  3  were  between  50  and  59.
On  the  other  hand,  Group  B  consisted  of  7  patients  between
the  ages  of  18  and  29,  3  were  between  30  and  39,  2  were
between  40  and  49  and  3  were  between  50  and  59.  A  statis-
tically  signiﬁcant  difference  was  not  found  in  the  mean  age
of  the  groups.  Regarding  BMI,  8  of  the  patients  who  partic-
ipated  in  the  study  had  a  normal  BMI  (18.5--24.9),  15  were
overweight  (25--29.9)  and  7  had  grade  I  obesity  (30--34.9).
Within  Group  A,  there  were  4  patients  with  a  normal  BMI,  10
overweight  and  1  with  grade  I  obesity,  whereas  in  Group  B
there  were  4  patients  with  normal  BMI,  5  overweight  and  6
with  obesity.  Once  again  no  signiﬁcant  differences  between
Group  A  and  Group  B  were  observed.  It  was  noted  that  20
of  the  patients  included  in  the  study  were  cataloged  as  ASA
I  and  10  as  ASA  II.  No  statistically  signiﬁcant  difference  was
observed  in  this  parameter.
As  for  the  Apfel  score,  of  the  30  patients  included  in  the
study,  5  presented  1  risk  factor  out  of  the  4  of  the  eval-
uation,  representing  a  risk  of  20%  of  suffering  PONV.  12
patients  presented  2  factors  (a  risk  of  40%);  12  patients  pre-
sented  3  factors  (a  risk  of  60%)  and  1  presented  4  factors
(a  risk  of  80%).  It  was  also  noted  that  out  of  the  30  indi-
viduals  of  the  study,  27  were  women,  20  were  non-smokers,
11  did  not  have  a  PONV  or  motion  sickness  background  and
postoperative  opioids  were  used  in  11  patients.  The  patient
c
i
PPatient  with  nausea  no.  2  1  2
Patient  with  nausea  no.  3  1  3
ho  presented  a  vomiting  episode  had  2  positive  variables  in
he  Apfel  score,  and  the  3  subjects  of  study  who  presented
ild  nausea  had  1,  2  and  3  positive  variables  respectively
see  Table  2).  No  statistically  signiﬁcant  differences  were
bserved  in  this  parameter  either.
Regarding  the  efﬁcacy  of  the  antiemetic  in  study,  1
atient  presented  vomiting  on  a  single  occasion  immediately
fter  extubation.  He  was  a  part  of  Group  B  (ondansetron).
 of  the  3  patients  who  presented  nausea  (number  2  in
he  Likert  scale)  belonged  to  Group  A  (metoclopramide  and
ndansetron)  and  presented  it  in  the  basal  hour  and  at  4  h.
t  ceased  without  rescue  medication.  The  third  of  the  3
atients  with  nausea  (number  2  in  the  Likert  scale)  belonged
o  Group  B  (ondansetron)  and  only  presented  it  during  the
asal  hour;  it  ceased  without  rescue  medication.  However,
o  differences  were  found  in  the  severity  of  the  nausea  or
he  satisfaction  of  the  patients  between  groups.  Thus,  the
ifference  between  both  groups  was  not  statistically  signif-
cant.
iscussion
ONV  is  among  the  most  frequent  complications  following
nesthesia  in  the  postoperative  of  laparoscopic  cholecystec-
omies;  42%  of  post-operated  laparoscopic  cholecystectomy
atients  present  nausea  and  vomiting,  which  translates  into
 greater  postoperative  discomfort  and  distress  for  patients,
n  top  of  the  fact  that  they  usually  remain  50%  longer  in  the
ecovery  room,  thus  altering  the  patient  ﬂow  of  the  hospi-
al  and  increasing  the  internment  costs  of  each  patient.  This
s  reduced  using  effective  antiemetics  in  a  single  dose  pre-
ious  to  its  presentation.  The  origin  of  this  complication  is
omplex  and  depends  on  a  wide  variety  of  factors  previously
entioned.
In  this  study,  the  treatment  groups  are  similar  in  relation
o  the  demographic  data  (inter-group  homogeneity),  surgi-
al  procedure,  and  type  of  anesthesia  and  analgesia  utilized
n  the  postoperative.
The  Apfel  score  was  used  to  assess  the  risk  of  presenting
ONV,  in  order  to  observe  its  ability  to  forecast  this  event
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146  
nd  because  it  includes  the  predisposed  factors  which  have
een  observed,  most  in  different  studies,  such  as  the  Lenka
oubravskaa  in  2010,  which  included  1954  patients.  Here,
hey  noted  the  fact  that  being  a  woman  increased  the  risk
f  presenting  PONV,  with  an  occurrence  of  24.5%  in  females
nd  6.3%  in  males.  On  the  other  hand,  smoking  seemed  to
e  a  protective  factor.  The  incidence  of  PONV  in  smokers
as  8.7%,  compared  to  non-smokers,  which  was  17.7%.  Also,
 high  PONV  incidence  was  observed  in  patients  with  obe-
ity  (BMI  over  30),  at  11.8%.  In  our  study,  we  were  able  to
bserve  that  the  4  patients  who  did  not  present  PONV  were
ll  women;  2  smokers  and  2  non-smokers;  2  with  a  PONV  or
otion  sickness  background;  and  none  were  administered
pioids  in  postoperative.  The  patient  who  presented  vomit-
ng  in  the  postoperative  had  2  positive  variables  in  the  Apfel
core,  and  the  3  patients  who  presented  mild  nausea  had
--3  variables,  which  cast  doubt  on  the  efﬁcacy  of  the  Apfel
core  as  the  most  sensitive  PONV  predictor.10
Different  studies  have  been  conducted  around  the  world,
here  different  managements  for  PONV  prevention  are
roposed.  The  use  of  combined  therapies  for  a  better  mana-
ement  is  recommended  in  many  of  them,  stressing  it  in
atients  with  high  risk  factors.11,12
In  a  study  conducted  in  Saudi  Arabia  by  Dr.  Mohamed
aguib  et  al.  they  included  132  patients  undergoing
aparoscopic  cholecystectomies,  who  were  randomly  admin-
stered  ondansetron  4  mg,  tropisetron  5  mg,  granisetron
 mg,  metoclopramide  10  mg  or  a  placebo  10  min  before
nesthetic  induction.  The  percentages  of  patients  free  of
omiting  were  65.5%,  52%,  48%,  29.2%  and  27.6%  in  the
ndansetron,  granisetron,  tropisetron,  metoclopramide  and
lacebo  groups,  respectively.  Prophylactic  antiemetic  treat-
ent  with  ondansetron  resulted  in  a  lower  PONV  incidence
p  = 0.02)  than  with  metoclopramide  or  placebos.  In  our
tudy,  we  were  able  to  observe  that  the  antiemetic  ther-
py  with  ondansetron  with  metoclopramide  in  a  single  dose
s  not  superior  to  that  of  just  ondansetron.13
onclusions
ntiemetic  combined  therapy  has  proven  in  some  stud-
es  to  be  more  effective  than  monotherapy  in  the  control
f  PONV.  In  our  study,  a  statistically  signiﬁcant  differ-
nce  was  not  found  in  the  efﬁcacy  of  polytherapy  with
ndansetron  with  metoclopramide  (4  mg  +  10  mg)  in  a  single
ose  and  monotherapy  with  ondansetron  (4  mg)  in  patients
ndergoing  laparoscopic  cholecystectomies  under  general
nesthesia.  However,  both  groups  of  patients  presented  a
ood  control  of  PONV  without  the  need  for  rescue  medica-
ions.
Regarding  the  Apfel  score  to  assess  the  risk  of  presenting
ONV,  in  the  present  study  we  did  not  ﬁnd  a  correlation
etween  the  risk  percentage  stated  by  the  score  and  the
atients  who  presented  PONV.
Therefore,  based  on  the  results  obtained  in  our  study  we
ccept  the  established  hypothesis  that  the  combination  of
1H.A.  Llanes-Garza  et  al.
ndansetron  and  metoclopramide  in  a  single  dose  is  as  effec-
ive  as  just  ondansetron  for  the  control  of  postoperative
ausea  and  vomiting.
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